The Guangdong-based company specializes in medical implants and regenerative biofilms for orthpedica materials, bone filling materials, artificial esophagus, ligaments, spinal membrane pateches etc. Under a license with Orthocell, an Australian startup, the company has introduced ACI (autologous chondrocyte implantation) technology. It cooperates closely with hospitals in the Guangdong area.

China Industrial Biotechnology Network, January 2, 2014

Shanghai is claimed to host 26 % of China’s pharmaceutical industry, with 24.000 highly skilled specialists working in this sector. An annual increase of 3.000 specialists is predicted, and personnel shortage may arise.

China Bio news release, January 3, 2013

In an article on Beijing Genomics Institute appearing on January 6, 2014, a review about BGI and her projects are provided

BGI news release, December 31, 2013

The polyketide-type antibiotic synthesized by a marine Actinomyces strain is under development as an immunosuppressive agent.

CAS news release, December 31, 2013-12-31

In an inventory published by Forbes on December 18, the most successful venture capital insitutions of China are presented. 28 have a focus on biological, pharmaceutical and health-related companies

China Bio news release, December 30, 2013-12-31

Using insect defensions such as navidefensin2-2 from Nasonia vitripennis, a peptide was obtained which was reistant to protease digestion and showed significant antimicrobial activity against several Gram-positive and –negative microorganisms.

Bin GAO et al., ACS Chem. Biol., DOI: 10.1021/cb400591d

Within just 2 years, the number of companies were reduced by 1/3. At present, the top 50 companies have a market share of over 30 %. Leading companies are Yuan Longping High-tech Agriculture Co., Shandong Denghai Seeds Co., Wilderness Kenfeng Seed Industry Co., China National Seed Group, Beijing Agritech Corporation, Beijing Gold Farming China Seed Industry Co., Liaoning East Asia Seed Industry Co., Henan Autumn Music Seed Technology Co. and Jiangsu Dahua Seed Industry Group Co.

China Bio news release, December 24, 2013

Among the $ 160 billion value of drug patents which expire in 2015, antiboides will constitute a significant part. Global monoclonal antibody drug market will reach $ 62.8 billion by 2015, and some of the patents will also expire. Chinese companies such as CITIC Healthcare and Watson Biological Co. are expected to profit most.

China Bio news release, December 24, 2013

After Chinese authorities in December rejected the import of 120.600 tons (5 batches) of GMO maize of the type MIR162, there is a debate about the quality of the 7 million tons of corn which are imported to China every year, and of which COFCO imports about 60 %. China will insist of importing only maize of approved GMO content.

CAS news release, December 24, 2013

A team around Peking University 3d Hospital sequenced the triads of the first and second polar bodies (PB1 and PB2) and the oocyte pronuclei from same female egg donors, phased the genomes of these donors with detected SNPs and determined the crossover maps of their oocytes. The research is hoped to promote in-vitro fertilization where live birth success is only 30 % at present.

China Bio press release, December 23, 2013

Chinese names are given to 12 craters and seven pits. The latest additions were given in 2010 following the Chang’e 2 project with a lunar orbiter.

China Science and Technology News, December 23, 2013

Upon completion, the cell R & D center for cord blood can save half a million of cord stem cells . A specialized hospital for hematopoietic stem cell transplantation will be constructed to carry out cell transplantation and treatment.

China Bio news release, December 22, 2013

Bacillus subtilis strdain PL83 is claimed to overproduce lysine and provide probiotic effects, susbstituting the use of antibiotics in aquaculture

CAS news release, December 21, 2013

After three years of initial research, the group identified 15 projects which will be commercialized, e. g. a dry chemistry analysis system, a micro biochemical analyzer, a portable chemiluminescence immunoassay analyzer, a miniature electrochemical immunoassay system, a low-cost high-performance portable ultrasound prototype instrument, a new type of flow cytometry for the minimally invasive treatment of frequently occurring high-power laser treatment , AO-CSLO real-time high-resolution retinal imaging devices, blood purification medical equipment etc. Some of the devices are already under clinical validation.

China Bio news release, December 20, 2013

Among the new foreign members is Aharon Ciechanover (Israel), 4 scientists from the USA and one each from France, Denmark, Brazil and India.

CAS news release, December 20, 2013

Within 5 years, the platform is expected to contain 20.000 sequences of over 120 families and over 1.400 species of plants.

CAS news release, December 20, 2013

In the framework of a joint program, ECUST will send two undergraduates per year for training in bioengineering to Biberach. Boehringer Ingelheim supports the students with a 5.700 €/y scholarship. In exchange, Biberach University sends students to ECUST in Shanghai. The program was started in March 2013.

China Bio news release, December 18, 2013

After 23 generations of inbreeding mini pigs, the group of Pingshu TANG has achievend an inbreeding coefficient of 0.993 and high genetic homogeneity, as shown by a genome-wide high density array for over 60.000 SNPs. 3.000 bulls have already been sold and applied to studies on human diseases, drug metabolism, safety of GM food and xenotransplantation.

China Bio news release, December 18, 2013

The centers will be coordinated by the CAS Xinjiang Institute of Ecology and Geography and be located in Xinjiang Uygur autonomous region. Three satellite branches, in Kyrgyzstan, Kazahkhstan and Takjikistan, are under construction and, after completion in 2014, will attenuate China’s role in the „silk road economic belt“.

CAS news release, December 18, 2013

By 2015, 160 billion USD of drug patents will expire, and global consumption of drugs will reach 1,1 trillion USD, with 60 to 70 % market share of generics.
Chinese specialists expect that this will provide excellent opportunities for Chinese enterprises focused on generics, e. g., on generic therapeutic antibodies.

China Bio news release, December 18, 2013